OSTEOMAX 40MG 10 F.C.TAB

Indication For the treatment and prevention of osteoporosis in women and Paget s disease of bone in both men and women. Mechanism of action The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate alendronate risedronate ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids thereby inhibiting FPP synthase an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women it reduces the elevated rate of bone turnover leading to on average